CD80 has been linked to promoting anti-tumor immune responses in multiple mouse models of cancer (Marchiori et al., 2019; Scarpa et al., 2015; Baskar et al., 1993; Chen et al., 1992; Ganesan et al., 2007; Haile et al., 2011; Hodge et al., 1994; Liu et al., 2001; Townsend and Allison, 1993), and exogenous administration of recombinant CD80 protein can promote anti-tumor immunity (Horn et al., 2018). The gene discussed is CD80; the disease is neoplasm.